<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Aapro M</dc:creator>
  <dc:creator>Arends J</dc:creator>
  <dc:creator>Bozzetti F</dc:creator>
  <dc:creator>Fearon K</dc:creator>
  <dc:creator>Grunberg SM</dc:creator>
  <dc:creator>Herrstedt J</dc:creator>
  <dc:creator>Hopkinson J</dc:creator>
  <dc:creator>Jacquelin-Ravel N</dc:creator>
  <dc:creator>Jatoi A</dc:creator>
  <dc:creator>Kaasa S</dc:creator>
  <dc:creator>Strasser F</dc:creator>
  <dc:date>2014</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">BACKGROUND
Weight loss and cachexia are common, reduce tolerance of cancer treatment and the likelihood of response, and independently predict poor outcome.


METHODS
A group of experts met under the auspices of the European School of Oncology to review the literature and-on the basis of the limited evidence at present-make recommendations for malnutrition and cachexia management and future research.


CONCLUSIONS
Our focus should move from end-stage wasting to supporting patients' nutritional and functional state throughout the increasingly complex and prolonged course of anti-cancer treatment. When inadequate nutrient intake predominates (malnutrition), this can be managed by conventional nutritional support. In the presence of systemic inflammation/altered metabolism (cachexia), a multi-modal approach including novel therapeutic agents is required. For all patients, oncologists should consider three supportive care issues: ensuring sufficient energy and protein intake, maintaining physical activity to maintain muscle mass and (if present) reducing systemic inflammation. The results of phase II/III trials based on novel drug targets (e.g. cytokines, ghrelin receptor, androgen receptor, myostatin) are expected in the next 2 years. If effective therapies emerge, early detection of malnutrition and cachexia will be increasingly important in the hope that timely intervention can improve both patient-centered and oncology outcomes.</dc:description>
  <dc:identifier>https://sonar.ch/global/documents/608</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1093/annonc/mdu085</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/24569913</dc:relation>
  <dc:source>Annals of oncology : official journal of the European Society for Medical Oncology. - 2014</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">cancer cachexia</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">malnutrition</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">nutritional support</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">review</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">systemic inflammation</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Body Composition</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">Cachexia</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">Early Diagnosis</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">Malnutrition</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">Molecular Targeted Therapy</dc:subject>
  <dc:subject xmlns:ns12="xml" ns12:lang="en">Neoplasms</dc:subject>
  <dc:subject xmlns:ns13="xml" ns13:lang="en">Pharmaceutical Preparations</dc:subject>
  <dc:subject xmlns:ns14="xml" ns14:lang="en">Practice Patterns, Physicians'</dc:subject>
  <dc:subject xmlns:ns15="xml" ns15:lang="en">Prognosis</dc:subject>
  <dc:subject xmlns:ns16="xml" ns16:lang="en">Weight Loss</dc:subject>
  <dc:title xmlns:ns17="xml" ns17:lang="en">Early recognition of malnutrition and cachexia in the cancer patient: a position paper of a European School of Oncology Task Force.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
